Baseline INSTI resistance (genotypic and phenotypic) and baseline viral load were highly significant predictors of response at week 24.
← all excerpts
Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.
1
—
—